Monopar Therapeutics director sells 3,142 shares

Q: How many MNPR shares did director Raymond Anderson sell, and at what prices?

Raymond Anderson reported selling 3,142 common shares on November 2, 2026, across four weighted-average prices: $66.16 for 840 shares (transactions ranged from $65.56 to $66.53), $67.06 for 600 ($66.88 to $67.57), $68.68 for 200 ($68.59 to $68.77), and $70.04 for 1,502 ($70.02 to $70.32).

Q: What were MNPR director Raymond Anderson's option exercise terms?

Anderson exercised options covering 1,402 shares at $29.9986 per share and 1,740 shares at $30.00 per share on November 2, 2026.

Anderson's reported transactions were under a Rule 10b5-1 plan executed May 26, 2026.

Available on EDGAR 11/04/2026 - 08:16 PM EST Accepted by SEC EDGAR 11/04/2026 - 08:15 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Monopar Therapeutics director Raymond Anderson exercised stock options covering 1,402 shares at $29.9986 and 1,740 shares at $30.00 on November 2, 2026. He also sold 3,142 common shares in four reported transactions: 840 at a weighted-average $66.16, 600 at $67.06, 200 at $68.68 and 1,502 at $70.04. The transactions were reported under a Rule 10b5-1 plan executed May 26, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,142 shares ($120K approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Anderson Raymond

Role Director

Sold 3,142 shs ($215K)

Approx. gross sale proceeds $215K

Approx. exercise cost $94K

Approx. pre-tax spread $120K

Type	Security	Shares	Price	Value
Exercise	Stock Option ^{F1, F2}	1,402	$0.00	$0.00
Exercise	Stock Option ^{F2, F3}	1,740	$0.00	$0.00
Exercise	Common Stock ^F2	1,402	$29.9986	$42K
Exercise	Common Stock ^F2	1,740	$30.00	$52K
Sale	Common Stock ^{F2, F4}	840	$66.16	$56K
Sale	Common Stock ^{F2, F5}	600	$67.06	$40K
Sale	Common Stock ^{F2, F6}	200	$68.68	$14K
Sale	Common Stock ^{F2, F7}	1,502	$70.04	$105K

Holdings After Transaction: Stock Option — 3,141 contracts (Direct); Common Stock — 5,373 shares (Direct)

Footnotes (7)

F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-26-2026.
F2. On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.
F3. On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.
F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.56 to $66.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.
F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.88 to $67.57, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.
F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.59 to $68.77, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.
F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.02 to $70.32, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

Key Figures

Options exercised: 1,402 shares at $29.9986 per share Options exercised: 1,740 shares at $30.00 per share Shares sold; weighted-average price: 840 shares at $66.16 per share +3 more

6 metrics

Options exercised 1,402 shares at $29.9986 per share November 2, 2026

Options exercised 1,740 shares at $30.00 per share November 2, 2026

Shares sold; weighted-average price 840 shares at $66.16 per share November 2, 2026

Shares sold; weighted-average price 600 shares at $67.06 per share November 2, 2026

Shares sold; weighted-average price 200 shares at $68.68 per share November 2, 2026

Shares sold; weighted-average price 1,502 shares at $70.04 per share November 2, 2026

Key Terms

Rule 10b5-1 Plan, weighted average price, stock options, vesting

4 terms

Rule 10b5-1 Plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 Plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

stock options financial

"the reporting person was granted stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vesting financial

"The options vest 6/42nds at the six-month anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MNPR shares did director Raymond Anderson sell, and at what prices?

Raymond Anderson reported selling 3,142 common shares on November 2, 2026, across four weighted-average prices: $66.16 for 840 shares (transactions ranged from $65.56 to $66.53), $67.06 for 600 ($66.88 to $67.57), $68.68 for 200 ($68.59 to $68.77), and $70.04 for 1,502 ($70.02 to $70.32).

What were MNPR director Raymond Anderson's option exercise terms?

Anderson exercised options covering 1,402 shares at $29.9986 per share and 1,740 shares at $30.00 per share on November 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderson Raymond

(Last)

(First)

(Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE

ILLINOIS

60091

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/02/2026		M⁽²⁾		1,402	A	$29.9986	6,775	D
Common Stock	11/02/2026		M⁽²⁾		1,740	A	$30	8,515	D
Common Stock	11/02/2026		S⁽²⁾		840	D	$66.16⁽⁴⁾	7,675	D
Common Stock	11/02/2026		S⁽²⁾		600	D	$67.06⁽⁵⁾	7,075	D
Common Stock	11/02/2026		S⁽²⁾		200	D	$68.68⁽⁶⁾	6,875	D
Common Stock	11/02/2026		S⁽²⁾		1,502	D	$70.04⁽⁷⁾	5,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$29.9986	11/02/2026		M⁽¹⁾			1,402	⁽²⁾	09/17/2027	Common Stock	1,402	$0	1,401	D
Stock Option	$30	11/02/2026		M⁽²⁾			1,740	⁽³⁾	08/08/2028	Common Stock	1,740	$0	1,740	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-26-2026.

2. On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

3. On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.56 to $66.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.88 to $67.57, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.59 to $68.77, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.02 to $70.32, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

	/s/ Quan Vu, Attorney-in-fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR